Arg34-GLP-1(7-37) CAS 204521-68-6

Enzymatic synthesis utilizes the catalytic action of enzymes to synthesize peptides. This method has the advantages of mild reaction conditions and fewer by-products. In the synthesis of the product, specific enzymes can be used to catalyze the formation of peptide bonds, thereby achieving efficient synthesis of target peptides.

In addition to the above methods, there are also some other biotechnology methods that can be used for the synthesis of Arg34-GLP-1(7-37), such as cell fusion technology, transgenic animal technology, etc. These technologies typically involve more complex biological operations and regulation, but can achieve more efficient synthesis and wider applications.

Different synthesis methods have their own advantages and disadvantages. Gene recombination technology can achieve large-scale and efficient synthesis, but the operation is complex and requires professional biological laboratory conditions. The chemical synthesis method has high flexibility and purity, but there are many synthesis steps and high costs. The enzymatic synthesis method has mild reaction conditions and fewer by-products, but the source and stability of the enzyme may limit its application. Therefore, when choosing a synthesis method, it is necessary to weigh the actual needs and conditions.

Gastrointestinal reactions: nausea, vomiting, diarrhea, indigestion, bloating, constipation .These reactions are usually mild and may gradually alleviate after a period of use.

Decreased appetite:Arg34-GLP-1 (7-37) has the effect of increasing satiety, which may lead to decreased appetite, thereby reducing calorie intake and aiding in weight management. However, for some patients, this may become an undesirable side effect.

Pancreatitis:Although rare, the use of GLP-1 analogs may increase the risk of pancreatitis. The symptoms of pancreatitis include severe abdominal pain, nausea, vomiting, etc.

Hypoglycemia:When the compound is used in combination with other blood glucose lowering drugs such as insulin or sulfonylurea, it may increase the risk of hypoglycemia. The symptoms of hypoglycemia include trembling, sweating, dizziness, weakness, and rapid heartbeat.

Allergic reactions:Some patients may experience allergic reactions to it, including rash, itching, difficulty breathing, etc. If allergic reactions occur, seek medical attention immediately.

Thyroid cancer risk:Studies have shown that GLP-1 analogs may increase the risk of medullary thyroid cancer. Therefore, caution should be exercised when using it for patients with a family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2.

Injection site reaction:For the substance in injection form, there may be reactions such as redness, swelling, and pain at the injection site. These reactions usually subside within a few days.

Monitoring and follow-up:During use, regular blood glucose monitoring, weight monitoring, and examinations of related organs such as the pancreas and thyroid should be conducted.

Patient education and communication:Patients should fully understand the side effects and risks associated with the compound and maintain close communication with healthcare providers during use.

The discovery of Arg34-GLP-1(7-37) was built on basic research of Glucagon-Like Peptide-1, with its origins tracing back to the 1980s. In 1986, scientists including Joel Habener and Svetlana Mojsov first identified Glucagon-Like Peptide-1 in the intestine. It is an active fragment produced by the cleavage of proglucagon via prohormone convertases, and one of the two major active forms of Glucagon-Like Peptide-1 in the human body. It was initially found to participate in blood glucose regulation and exert glucose-dependent insulinotropic effects. Earlier, Habener's team had predicted the existence of such glucagon-related peptides through studies on fish proglucagon, laying the foundation for the subsequent discovery of the active fragment.

With in-depth investigations into the physiological functions of Glucagon-Like Peptide-1, scientists found that native Glucagon-Like Peptide-1 is readily hydrolyzed and inactivated by dipeptidyl peptidase-4 (DPP-4) in vivo, with an extremely short half-life, making it difficult to directly apply in research and drug development. In subsequent studies, researchers explored optimization strategies through structural modification. Unexpectedly, they found that replacing lysine (Lys) at position 34 of native Glucagon-Like Peptide-1 with arginine (Arg) yielded the product, which not only retained the original biological activity but also exhibited significantly enhanced receptor agonism. Furthermore, it provided a stable scaffold for further structural modification and half-life extension, becoming a crucial cornerstone in the research and development of Glucagon-Like Peptide-1 receptor agonist drugs, and advancing the progress of related hypoglycemic and anti-obesity medications.